isoxazoles and ve 821
isoxazoles has been researched along with ve 821 in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Biskup, E; Gniadecki, R; Naym, DG | 1 |
| Andrs, M; Gorecki, L; Korabecny, J; Rezacova, M | 1 |
Reviews
1 review(s) available for isoxazoles and ve 821
| Article | Year |
|---|---|
Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Drug Discovery; Drug Synergism; Humans; Isoxazoles; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Pyrazines; Signal Transduction; Sulfones; Treatment Outcome | 2020 |
Other Studies
1 other study(ies) available for isoxazoles and ve 821
| Article | Year |
|---|---|
Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation.
Topics: Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Flow Cytometry; Histones; Humans; Isoxazoles; Lymphoma, T-Cell, Cutaneous; Phosphorylation; Photochemotherapy; Photosensitizing Agents; Pyrazines; Quinolines; Quinuclidines; RNA, Small Interfering; Sulfones; Tumor Cells, Cultured; Ultraviolet Rays | 2016 |